Tetra Bio-Pharma Inc. today announced a change in their Drug Development Plan (DDP) priorities. This will allow Tetra to rapidly leverage the PANAG pipeline and expertise and align its research programs on indications with unmet medical needs or a higher return on investment (ROI).